Close

Please fill all fields and submit the form.

Name:
Email:

Phone:

Notes:



Close

Please fill out all fields in the form. Please be as detailed as possible. We will respond with pricing and availability within 1-2 business days.

Name:
Company/Institution:

Phone:
Email:

Disease:

Organ/Tissue type:

Format:

Number of patients/donors required for the study:

Clinical Specifications:

Applications/Research topic:

KRAS Seven Mutations Detection Kit

KRAS Seven Mutations Detection Kit Description

The KRAS gene mutation status of colorectal cancer patients is relevant to drug resistance of targeted medicines such as tyrosine kinase inhibitors. Patients with wild-type KRAS gene are much more likely to benefit from the Erbitux (Cetuximab) or Vectibix (Panitumumab), compared to patients with a mutant KRAS gene. The European Drug Administration Organization and US FDA recommended the employment of KRAS gene mutation test prior to the usage of targeted medicine Erbitux and and Vectibix in the treatment of colorectal cancer.

Intended use: RUO

Mutations:

Gly12Asp (GGT>GAT)

Gly12Ala (GGT>GCT)

Gly12Val (GGT>GTT)

Gly12Ser (GGT>AGT)

Gly12Arg (GGT>CGT)

Gly12Cys (GGT>TGT)

Gly13Asp (GGC>GAC)